ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Amendment to Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics

ME Staff 8-k
-
0

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Amendment to Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 5.05Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On July20, 2017, the Board of Directors of Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) approved and adopted a revised and updated Code of Business Conduct and Ethics (the “Updated Code”), which applies to all directors, officers and employees of the Company. The Updated Code replaced the Company’s prior Code of Business Conduct and Ethics adopted in July2015 and reflects, among other matters, clarifications and revisions relating to conflicts of interest, compliance with laws, reporting and enforcement, and other matters intended to update the Company’s Code of Business Conduct and Ethics.

The foregoing summary of the Updated Code does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Updated Code, which is filed as Exhibit14.1 to this Current Report on Form8-K and is incorporated by reference herein. A copy of the Updated Code is available in the Investors section of Adaptimmune’s website (http://www.adaptimmune.com) under the heading “Governance.” The information contained on or accessible through the Company’s website shall not be deemed to be a part of this Current Report on Form8-K.

The information contained in Item 9.01 of this Form8-K, including the attached Exhibit14.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished as part of this Report on Form8-K:

ExhibitNo.

DescriptionofExhibit

14.1

Adaptimmune Therapeutics plc Code of Business Conduct and Ethics, effective July20, 2017


Adaptimmune Therapeutics PLC Exhibit
EX-14.1 2 a17-18309_1ex14d1.htm EX-14.1 Exhibit 14.1   ADAPTIMMUNE THERAPEUTICS PLC CODE OF BUSINESS CONDUCT AND ETHICS   (As Adopted by the Board of Directors of Adaptimmune Therapeutics plc on 20 July 2017,…
To view the full exhibit click here

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.